UB Paderborn / Katalog / Suche / in CDI

Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies

Cell reports (Cambridge), 2019-05, Vol.27 (8), p.2411-2425.e9

2019

Link zum Volltext

Verfügbarkeit prüfen

Plasmacytoid dendritic cell–derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists

Blood, 2010-03, Vol.115 (10), p.1949-1957

2010

Link zum Volltext

Verfügbarkeit prüfen

CD73-Mediated Immunosuppression Is Linked to a Specific Fibroblast Population That Paves the Way for New Therapy in Breast Cancer

Cancers, 2021-11, Vol.13 (23), p.5878

2021

Link zum Volltext

Verfügbarkeit prüfen

Nucleic acid agonists for Toll‐like receptor 7 are defined by the presence of uridine ribonucleotides

European Journal of Immunology, 2006-12, Vol.36 (12), p.3256-3267

2006

Link zum Volltext

Verfügbarkeit prüfen

The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocyte/macrophage colony-stimulating factor

The Journal of experimental medicine, 2002-04, Vol.195 (7), p.953-958

2002

Link zum Volltext

Verfügbarkeit prüfen

S258: IPH6501 IS A FIRST‐IN‐CLASS TETRASPECIFIC ANTIBODY‐BASED NATURAL KILLER CELL ENGAGER THERAPEUTIC DEVELOPED FOR THE TREATMENT OF B‐CELL NON‐HODGKIN’S LYMPHOMAS

HemaSphere, 2023-08, Vol.7 (S3), p.e1234532-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Type I interferon dependence of plasmacytoid dendritic cell activation and migration

The Journal of experimental medicine, 2005-04, Vol.201 (7), p.1157-1167

2005

Link zum Volltext

Verfügbarkeit prüfen

The toll-like receptor agonist imiquimod is active against prions

PloS one, 2013-08, Vol.8 (8), p.e72112-e72112

2013

Link zum Volltext

Verfügbarkeit prüfen

Mouse Strain Differences in Plasmacytoid Dendritic Cell Frequency and Function Revealed by a Novel Monoclonal Antibody

The Journal of immunology (1950), 2003-12, Vol.171 (12), p.6466-6477

2003

Link zum Volltext

Verfügbarkeit prüfen

TLR3 as a Biomarker for the Therapeutic Efficacy of Double-stranded RNA in Breast Cancer

Cancer research (Chicago, Ill.), 2011-03, Vol.71 (5), p.1607-1614

2011

Link zum Volltext

Verfügbarkeit prüfen

Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity

Nature Immunology, 2005-10, Vol.6 (10), p.1011-1019

2005

Link zum Volltext

Verfügbarkeit prüfen

Murine Plasmacytoid Dendritic Cells Initiate the Immunosuppressive Pathway of Tryptophan Catabolism in Response to CD200 Receptor Engagement

The Journal of immunology (1950), 2004-09, Vol.173 (6), p.3748-3754

2004

Link zum Volltext

Verfügbarkeit prüfen

Poly(I:C) induces intense expression of c-IAP2 and cooperates with an IAP inhibitor in induction of apoptosis in cancer cells

BMC cancer, 2010-06, Vol.10 (1), p.327-327, Article 327

2010

Link zum Volltext

Verfügbarkeit prüfen

Ligand and cytokine dependence of the immunosuppressive pathway of tryptophan catabolism in plasmacytoid dendritic cells

International immunology, 2005-11, Vol.17 (11), p.1429-1438

2005

Link zum Volltext

Verfügbarkeit prüfen

Quantitative analysis of Th1, Th2 and TGF‐β1 cytokine expression in tumor, TIL and PBL of non‐small cell lung cancer patients

International journal of cancer, 1998-07, Vol.77 (1), p.7-12

1998

Link zum Volltext

Verfügbarkeit prüfen

Production of type I interferons: plasmacytoid dendritic cells and beyond

The Journal of experimental medicine, 2005-08, Vol.202 (4), p.461-465

2005

Link zum Volltext

Verfügbarkeit prüfen

Toll-like receptor 3 in Epstein-Barr virus-associated nasopharyngeal carcinomas: consistent expression and cytotoxic effects of its synthetic ligand poly(A:U) combined to a Smac-mimetic

Infectious agents and cancer, 2012-12, Vol.7 (1), p.36-36, Article 36

2012

Link zum Volltext

Verfügbarkeit prüfen

Plasmacytoid Dendritic Cells Mediate Oral Tolerance

Immunity (Cambridge, Mass.), 2008-09, Vol.29 (3), p.464-475

2008

Link zum Volltext

Verfügbarkeit prüfen

A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies

Oncotarget, 2018-04, Vol.9 (25), p.17675-17688

2018

Link zum Volltext

Verfügbarkeit prüfen

IPH6501 Is a Novel NKp46-Targeting Tetraspecific Antibody-Based Natural Killer Cell Engager Therapeutic (ANKET) Armed with a Non-Alpha IL-2 Variant and Developed for the Treatment of CD20-Positive Malignancies

Blood, 2022-11, Vol.140 (Supplement 1), p.11559-11559

2022

Link zum Volltext

Verfügbarkeit prüfen

Human XCR1+ dendritic cells derived in vitro from CD34+ progenitors closely resemble blood dendritic cells, including their adjuvant responsiveness, contrary to monocyte-derived dendritic cells

The Journal of immunology (1950), 2014-08, Vol.193 (4), p.1622-1635

2014

Link zum Volltext

Verfügbarkeit prüfen

IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma

Cancer research (Chicago, Ill.), 2014-11, Vol.74 (21), p.6060-6070

2014

Link zum Volltext

Verfügbarkeit prüfen

Production of type I interferons

The Journal of experimental medicine, 2005-08, Vol.202 (4), p.461-465

2005

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies

IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial

Plasmacytoid dendritic cell–derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists

CD73-Mediated Immunosuppression Is Linked to a Specific Fibroblast Population That Paves the Way for New Therapy in Breast Cancer

Nucleic acid agonists for Toll‐like receptor 7 are defined by the presence of uridine ribonucleotides

The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocyte/macrophage colony-stimulating factor

S258: IPH6501 IS A FIRST‐IN‐CLASS TETRASPECIFIC ANTIBODY‐BASED NATURAL KILLER CELL ENGAGER THERAPEUTIC DEVELOPED FOR THE TREATMENT OF B‐CELL NON‐HODGKIN’S LYMPHOMAS

Type I interferon dependence of plasmacytoid dendritic cell activation and migration

The toll-like receptor agonist imiquimod is active against prions

Mouse Strain Differences in Plasmacytoid Dendritic Cell Frequency and Function Revealed by a Novel Monoclonal Antibody

TLR3 as a Biomarker for the Therapeutic Efficacy of Double-stranded RNA in Breast Cancer

Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity

Murine Plasmacytoid Dendritic Cells Initiate the Immunosuppressive Pathway of Tryptophan Catabolism in Response to CD200 Receptor Engagement

Poly(I:C) induces intense expression of c-IAP2 and cooperates with an IAP inhibitor in induction of apoptosis in cancer cells

Ligand and cytokine dependence of the immunosuppressive pathway of tryptophan catabolism in plasmacytoid dendritic cells

Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control

Quantitative analysis of Th1, Th2 and TGF‐β1 cytokine expression in tumor, TIL and PBL of non‐small cell lung cancer patients

Production of type I interferons: plasmacytoid dendritic cells and beyond

Toll-like receptor 3 in Epstein-Barr virus-associated nasopharyngeal carcinomas: consistent expression and cytotoxic effects of its synthetic ligand poly(A:U) combined to a Smac-mimetic

Plasmacytoid Dendritic Cells Mediate Oral Tolerance

A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies

IPH6501 Is a Novel NKp46-Targeting Tetraspecific Antibody-Based Natural Killer Cell Engager Therapeutic (ANKET) Armed with a Non-Alpha IL-2 Variant and Developed for the Treatment of CD20-Positive Malignancies

Human XCR1+ dendritic cells derived in vitro from CD34+ progenitors closely resemble blood dendritic cells, including their adjuvant responsiveness, contrary to monocyte-derived dendritic cells

IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma

Production of type I interferons

Suchergebnisse filtern